We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

122 hedge funds and large institutions have $136M invested in TCR2 Therapeutics Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 34 increasing their positions, 35 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 32

4% more funds holding

Funds holding: 117 → 122 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 35

50% less capital invested

Capital invested by funds: $270M → $136M (-$134M)

57% less call options, than puts

Call options by funds: $123K | Put options by funds: $288K

Holders
122
Holders Change
+5
Holders Change %
+4.27%
% of All Funds
1.88%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
40
Increased
34
Reduced
35
Closed
32
Calls
$123K
Puts
$288K
Net Calls
-$165K
Net Calls Change
+$2.67M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$7.23M
2
Bank of America
Bank of America
North Carolina
+$7.08M
3
Renaissance Technologies
Renaissance Technologies
New York
+$4.36M
4
BBA
Baker Bros. Advisors
New York
+$3.6M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.77M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$15.4M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$11.9M
3
State Street
State Street
Massachusetts
-$6.25M
4
FLAM
First Light Asset Management
Minnesota
-$5.28M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$4.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$229K +$100K +16,039 +49%
OC
52
Oppenheimer & Co
New York
$211K -$20.9K -3,350 -7%
Squarepoint
53
Squarepoint
New York
$195K +$161K +25,678 +158%
GCM
54
Graham Capital Management
Connecticut
$189K +$254K +40,611 New
Prudential Financial
55
Prudential Financial
New Jersey
$186K +$249K +39,895 New
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$177K -$3.86K -617 -2%
ECM
57
ExodusPoint Capital Management
New York
$173K -$177K -28,384 -43%
T. Rowe Price Associates
58
T. Rowe Price Associates
Maryland
$169K +$227K +36,281 New
PCM
59
Prelude Capital Management
New York
$169K +$227K +36,300 New
XSC
60
X-Square Capital
Puerto Rico
$149K – – –
VF
61
Virtu Financial
New York
$149K +$200K +31,912 New
SSA
62
Schonfeld Strategic Advisors
New York
$145K -$1.32M -210,561 -87%
Ensign Peak Advisors
63
Ensign Peak Advisors
Utah
$144K +$193K +30,860 New
Connor, Clark & Lunn Investment Management (CC&L)
64
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$134K +$27.8K +4,443 +18%
AG
65
Algert Global
California
$129K -$154K -24,584 -47%
AllianceBernstein
66
AllianceBernstein
Tennessee
$127K – – –
Voloridge Investment Management
67
Voloridge Investment Management
Florida
$125K +$167K +26,773 New
JMPWA
68
JP Morgan Private Wealth Advisors
California
$119K +$160K +25,616 New
GTCM
69
Gyon Technologies Capital Management
New Jersey
$113K +$152K +24,248 New
CANY
70
Caxton Associates (New York)
New York
$106K +$142K +22,784 New
SG Americas Securities
71
SG Americas Securities
New York
$105K -$22K -3,517 -13%
Walleye Trading
72
Walleye Trading
New York
$105K +$6.72K +1,075 +5%
Wells Fargo
73
Wells Fargo
California
$104K +$463 +74 +0.3%
MAM
74
Marquette Asset Management
Minnesota
$93K +$125K +19,979 New
HSBC Holdings
75
HSBC Holdings
United Kingdom
$92K +$119K +19,094 New
1 2
3
4 5

TCRR Hedge Fund Activity: Q4 2021 in Review

122 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2021, worth a combined $136M — down 50% from $270M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new TCRR positions and 32 closed out — a net gain of 8 holders — while 34 added to existing stakes and 35 trimmed.

The largest buyer was Millennium Management, adding an estimated $7.23M. The largest seller was Redmile Group, cutting an estimated $15.4M.

  • 122 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2021, up from 117 in Q3 2021.
  • Funds reported $136M of TCR2 Therapeutics Inc. Common Stock stock for Q4 2021, down 50% quarter-over-quarter.
  • 40 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2021 and 32 closed out, a net change of +8 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2021 was Millennium Management, an estimated $7.23M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2021 was Redmile Group, an estimated $15.4M sold.

Based on aggregated 13F filings for Q4 2021.